Business
Medison Issues Letter to Shareholders of Knight Therapeutics, Outlining Qualified, Independent Director Nominees and Common-Sense Plan to Build Value
Medison Issues Letter to Shareholders of Knight Therapeutics, Outlining Qualified, Indepen...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nMedison Issues Letter to Shareholders of Knight Therapeutics, Outlining Qualified, Independent Director Nominees and Common-Sense Plan to Build Value\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nPETACH TIKVA, Israel, April 16, 2019\n\n\n\nKnight has a tremendous opportunity to create value, but is currently on the wrong path Medison's experienced and independent director nominees are committed to pursuing a common-sense, low-risk plan that creates value for all shareholders More information on the director nominees and Medison's comprehensive plan for Knight, including plans to return at least $100 million of excess capital to Knight shareholders in the form of a special dividend or share buyback, is available at www.NewDayForKnight.com PETACH TIKVA, Israel, April 16, 2019 /CNW/ - Medison Biotech (1995) Ltd. (\"Medison\"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX: GUD) (\"Knight\" or the \"Company\"), today issued an open letter to Knight shareholders.  Included below, the letter provides an overview of Medison's highly qualified, independent director nominees and its common-sense, low-risk plan to build long-term value for the Company and its shareholders.\n\"Knight has a tremendous opportunity to create shareholder value and save patient lives, which is exactly what we've successfully done with Medison in Israel,\" said Meir Jakobsohn, CEO of Medison. \"But today, Knight is on the wrong path, as is clear from its poor operating results and share price performance.  Our sole interest in this campaign is to unlock value for all Knight shareholders, but to do that the Company requires an experienced, independent Board and a focused, common-sense plan.\"\nMr. Jakobsohn continued, \"In addition to me, our five exceptional nominees are truly independent and highly experienced executives with proven track records of improving results in pharma companies around the world.  They will help Knight realize its potential with a plan that targets a multi-bill...